Keep REMS ed optional: AAFP

At an FDA public meeting on issues and challenges around risk evaluation and mitigation strategy (REMS), the AAFP urged the agency to keep REMS-specific CME for extended-release and long-acting opioids voluntary, reported AAFP News Now.

Ann Karty, MD, medical director of the AAFP division of CME, said a prescriber-education mandate could impact patient access to those drugs.

It could also create confusion for doctors who are licensed in multiple states.

“If you start adding more requirements… there is the potential that some will not participate,” Karty told AAFP News Now.
You must be a registered member of MMM to post a comment.

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.